2005 NNFF Consortium for NF1, NF2 and Schwannomatosis

描述（由申请人提供）：申请资金支持国家神经纤维瘤病基金会国际联盟关于NF1、NF2和神经鞘瘤病的分子和细胞生物学的2005年会议，会议将于2005年6月5日至8日在科罗拉多州阿斯彭的Jerome酒店举行。从1985年第一次会议开始，这些会议提供了一个定期论坛，汇集了科学家和临床医生，分享他们最新的研究成果和经验，并形成新的合作企业。NNFF联盟在许多重要的研究成果中发挥了重要作用，包括基因的克隆、蛋白质功能的探索、动物模型的开发以及促进临床试验的患者和临床医生网络的建立。快速的科学进步及其对临床实践的转化使得年度会议在科学上既富有成效又必要。2005年的联盟会议将是一个公开的会议，面向一般科学界。五场平台会议中的每一场都将有该领域的专家参加，他们将指导讨论邀请发言者提出的工作和选定提交的摘要。将鼓励年轻的研究人员参加，根据以前的联合会会议，组织者预计演讲者将有相当大的比例是年轻的研究人员。此外，来自NF社区以外的主讲人的长篇演讲将被纳入科学会议。还将举行两次海报会议，这将允许调查人员介绍未被选为口头会议之一的摘要。除了更新NF1、NF2和神经鞘瘤病研究人员的最新研究进展外，本次会议将有助于确定我们知识中的关键空白，以及解决这些空白的策略和合作，并将在开发针对这些疾病并发症的改进疗法方面发挥重要作用，对发育神经生物学和癌症研究领域具有广泛的影响。

DESCRIPTION (provided by applicant): Funding is requested to support the 2005 meeting of the National Neurofibromatosis Foundation International Consortium for the Molecular and Cell Biology of NF1, NF2 and Schwannomatosis, to be held June 5-8, 2005, at the Hotel Jerome in Aspen, Colorado. Beginning with the first meeting in 1985, these conferences have provided a regular forum to bring together scientists and clinicians to share their latest research findings and experiences and to form new collaborative ventures. NNFF Consortia have been instrumental in a number of key research accomplishments, including the cloning of the genes, exploration of protein functions, development of animal models/and creation of a network of patients and clinicians to facilitate clinical trials. The rapid scientific progress and subsequent translation to clinical practice has made annual meetings both scientifically productive and necessary. The 2005 Consortium meeting will be an open meeting advertised to the general scientific community. Each of five platform sessions will include experts in the field who will guide discussion of the presented work from invited speakers and selected submitted abstracts. Participation by junior investigators will be encouraged and the organizers anticipate, on the basis of previous Consortium meetings, that a substantial percentage of the speakers will be young investigators. In addition, longer talks by keynote speakers from outside the NF community will be incorporated into the scientific sessions. Two poster sessions will also be held which will allow investigators to present abstracts not selected for one of the oral sessions. In addition to updating investigators working on NF1, NF2, and schwannomatosis on the latest research developments, this meeting will help to identity critical gaps in our knowledge as well as strategies and collaborations to address them and will play an essential role in developing improved therapies for the complications of these disorders with broad implications to the fields of developmental neurobiology and cancer research.